MARKET

ONCE

ONCE

Spark
NASDAQ

Real-time Quotes | Nasdaq Last Sale

113.57
0.00
0.00%
Delisted 09:30 02/27 EST
OPEN
--
PREV CLOSE
110.75
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
114.20
52 WEEK LOW
34.53
MARKET CAP
4.38B
P/E (TTM)
-17.3501
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ONCE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 12 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ONCE stock price target is 105.12 with a high estimate of 115.00 and a low estimate of 48.00.

EPS

ONCE News

More
  • A Perspective On Biopharma's Record M&A Run In 2019
  • Benzinga · 12/23/2019 19:57
  • Roche finalizes Spark takeover
  • seekingalpha · 12/17/2019 19:29
  • Spark Therapeutics CEO: 'We get to write the next chapter'
  • American City Business Journals · 12/17/2019 18:00
  • Approval Of The Spark Deal Only Part Of An Expanding R&D-Driven Opportunity At Roche
  • Seeking Alpha - Article · 12/17/2019 17:50

Industry

Biotechnology & Medical Research
-1.79%
Pharmaceuticals & Medical Research
-1.04%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About ONCE

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.
More

Webull offers kinds of Spark Therapeutics Inc stock information, including NASDAQ:ONCE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCE stock news, and many more online research tools to help you make informed decisions.